General Motors Unfr...
Health Care: Drugs
Gilead Sciences Inc (GILD: NASDAQ)
$51.58 -0.29 | -0.56%
05/16/12 - 04:00 PM ET
6.72M / 7.94M
Vol / Avg. Vol:51.85 / 51.87
Open / Prev. Close:51.57 - 52.11
Today's Range:34.45 - 56.50
52 Wk Range:26.73%
Performance YTD:TheStreet Rating:
Portfolios with GILD
- Portfolio NameUser Type
- ProJohn Griffin - Blue Ridge C...
- ProSteven Cohen - SAC Capital
- UserPerpetual growers
- Contributor10 Stocks Owned by the Best...
- UserEverett Bishop Portfolio 1
- ContributorStocks With Big Insider Buy...
- ProMoore Capital
- ContributorHealth Care Stocks Bought a...
- UserRick McGeehan Portfolio 1
- Contributor10 Health Care Stocks to Watch
Latest GILD Headlines from TheStreet
- A Health Care Fortnight for the Record Books 05.14.12 | 07:05 am
- Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 05.11.12 | 04:05 pm
- Vertex Is the Next Gilead Sciences or Alexion 05.07.12 | 11:05 am
- Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix 05.07.12 | 07:05 am
- Gilead Sciences Inc (GILD): Today's Featured Health Care Loser 05.04.12 | 05:05 pm
- 26 Drugs Facing FDA Approval in 2012 05.02.12 | 01:05 pm
- Gilead Sciences Inc (GILD): Today's Featured Drugs Loser 04.27.12 | 05:04 pm
- Biotech Stock Mailbag: AVI, Aveo, Spectrum 04.27.12 | 06:04 am
- Gilead Sciences Management Discusses Q1 2012 Results - Earnings Call Transcript 04.26.12 | 10:04 pm
- Amgen Goes to Turkey, Loses Biotech Cred 04.25.12 | 09:04 am
Press Releases for GILD
- FDA Advisory Committee Supports Approval Of Gilead’s Once-Daily Quad Single Tablet Regimen For HIV - Business Wire 05.11.12 | 03:05 pm
- FDA Advisory Committee Supports Approval Of Gilead’s Truvada® For Reducing The Risk Of Acquiring HIV - Business Wire 05.10.12 | 08:05 pm
- Gilead Sciences To Present At The Deutsche Bank 37th Annual Health Care Conference On Tuesday, May 8 - Business Wire 05.01.12 | 04:05 pm
- Gilead Sciences To Release First Quarter 2012 Financial Results On Thursday, April 26, 2012 - Business Wire 04.19.12 | 04:04 pm
- Gilead Announces Early Sustained Virologic Response Rates For GS-7977 Plus Ribavirin In Genotype 1 Treatment-Naïve Hepatitis C Patients - Business Wire 04.19.12 | 05:04 am
- Gilead Announces Sustained Virologic Response Data For 12-Week Regimen Of GS-7977 Plus Pegylated Interferon And Ribavirin In Genotype 1 Hepatitis C Patients - Business Wire 04.19.12 | 05:04 am
- Gilead Sciences To Present New Hepatitis B And C Data At European Conference On Liver Disease This Week - Business Wire 04.18.12 | 07:04 am
- Data Show Gilead’s Quad Regimen For HIV Non-Inferior To Protease-Based Regimen At 48 Weeks In Second Pivotal Phase 3 Study - Business Wire 03.08.12 | 07:03 pm
- Gilead’s Quad Single Tablet Regimen For HIV Non-Inferior To Atripla® In Pivotal Phase 3 Study - Business Wire 03.07.12 | 03:03 pm
- Gilead Sciences Quad Study 102 Results Conference Call On Wednesday, March 7, 2012 - Business Wire 03.06.12 | 04:03 pm
Partner Headlines for GILD
- The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases - Zacks 05.15.12 | 09:05 am
- Merck's Q1 Results Mixed; All Eyes On Drug Pipeline - Investor's Business Daily 04.27.12 | 06:04 pm
- Higher Costs Hurt Gilead - Analyst Blog - Zacks 04.27.12 | 10:04 am
- Top Undervalued High Conviction Outperforming Picks From Eaton Vance's $47 Billion Q1 Filng - Seeking Alpha 04.20.12 | 10:04 pm
- 6 Biotech Stocks With Huge Potential In May - Seeking Alpha 04.11.12 | 08:04 am
- Choose CRAP Stocks For Investment Success - Seeking Alpha 04.04.12 | 09:04 am
- BARCLAYS PRESENTS: The 39 Most Innovative Public Companies In America (NFLX, WMS, GIS, ABT, BDX, GILD, HOLX, ILMN, ISRG, LIFE, MDT, QGEN, QSII, RMD, STJ, TECH, VAR, WST, EMR, HEI, LECO, TGI, WWD, AAPL, ADTN, ADVS, BRCM, CREE, CSCO, DLB, FLIR, GOOG, NTAP, NUAN, ORCL, SYNA, TQNT, VPRT, MON) - Business Insider 04.02.12 | 10:04 am
- What Stocks Are Hedge Funds Holding? - Seeking Alpha 03.09.12 | 09:03 am
- FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris - Seeking Alpha 03.02.12 | 05:03 pm
- Deutsche Bank Reiterates Buy, $57 PT on Gilead Sciences - Benzinga 02.27.12 | 09:02 am
